Incidence and risk factors of antidepressant withdrawal symptoms: a meta-analysis and systematic review.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomized controlled trials and observational studies
PubMed 39394455 · doi:10.1038/s41380-024-02782-4
What was done
Authors searched six major databases (PubMed, Embase, PsycINFO, MEDLINE, CINAHL, Cochrane Central) through December 31, 2023, for randomized double-blind trials, longitudinal studies, and cross-sectional studies evaluating antidepressant withdrawal syndrome (AWS). A random-effects model was used to calculate pooled incidence rates across 35 included studies (11 RCTs plus observational and survey studies).
What was found
The pooled incidence of AWS across all studies was 42.9%, and 44.4% when restricted to 11 RCTs. Most studies evaluated 8–12 weeks of treatment, with symptoms emerging within 2 weeks and monitored for <4 weeks. Incidence by class was 29.7% for SNRIs, 45.6% for SSRIs, and 59.7% for TCAs (p = 0.221). Treatment duration showed a dose-response pattern: 35.1% at 6–12 weeks, 42.7% at 12–24 weeks, and 51.4% at >24 weeks. Tapering resulted in a lower incidence than abrupt cessation (34.5% vs 42.5%), though the difference was not statistically significant (p = 0.484). Identified risk factors included female sex, younger age, early adverse effects, higher doses, longer duration, abrupt stoppage, lower drug clearance, and serotonin 1A receptor gene variations.
Why it matters
This review establishes that antidepressant discontinuation symptoms affect more than 40% of patients and increase with treatment duration, emphasizing the need for patient counseling and planned discontinuation strategies.
Limits
The abstract does not state the total number of participants across the 35 included studies. Most primary studies evaluated short-term use (8–12 weeks) with brief follow-up periods (<4 weeks), limiting generalizability to long-term users. Comparisons between drug classes and tapering vs. abrupt cessation did not reach statistical significance.
Cited by
- supports SSRIs have a side effect rate of approximately 50% and a withdrawal/discontinuation effect rate of approximately 50%.